Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06211530 · ClinicalTrials.gov registry record · NA
Wireless Disposable SpO2 Sensor Hypoxia Testing
A NA study, sponsored by GE Healthcare.
- Completed
- Registry status
- NA
- Development phase
- 32
- Enrollment target
NCT06211530: Completed NA study, sponsored by GE Healthcare.
NCT06211530 is a NA study that has completed, run by GE Healthcare. The registered enrollment target is 32 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06211530, a NA study, has completed, sponsored by GE Healthcare.
- COMPLETED
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of the study is to collect SpO2 data with simultaneous transfer standard SpO2 measurements data on human participants.
Primary Outcome
The collection of SpO2 percentage sensor data with simultaneous transfer standard SpO2 percentage measurements (simulating blood sample SpO2) from each subject enrolled in the study.
Interventions
- DEVICE SpO2 Sensor Testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2024-01-30 |
| Est. Completion | 2024-02-08 |
| Phase | NA |
What the finished NCT06211530 record still lists
NCT06211530 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which SpO2 Sensor Testing is the first listed.
NCT06211530 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06211530 about?
NCT06211530 is a clinical study titled "Wireless Disposable SpO2 Sensor Hypoxia Testing". The purpose of the study is to collect SpO2 data with simultaneous transfer standard SpO2 measurements data on human participants.
What is the current status of trial NCT06211530?
This trial is currently completed. It is a NA study. The enrollment target is 32 participants. The study started on 2024-01-30. Estimated completion is 2024-02-08.
What interventions are being tested in trial NCT06211530?
The interventions under investigation include: SpO2 Sensor Testing (DEVICE).
Who is sponsoring clinical trial NCT06211530?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06211530's enrollment target sits among peer trials
32 1578th of 2000 higher than 409 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI